IASO THERAPEUTICS, INC.

EAST LANSING, MI · Founded 2018 · Biotech · Private

Bacteriophage mutant Qβ virus-like particle platform for conjugate vaccines against bacterial infections

Claim this profile

Follows are private to you and power your alerts

Updated Oct 23, 2026 · iasotherapeutics.com

Sector: Biotech
Headquarters: EAST LANSING, MI
Founded: 2018
Latest Form D: $570K, Jan 2026
Total capital: $4.7M

Federal grants: $3.7M; 8 awards · 2019–2026; Rank in peer group#374 of 514
Private capital raised: $1M; 2 Form D · last Jan 2026; 9 months since last filing
Federal contracts: None on recordNo federal contract awards found.
Granted patents: None on recordNo USPTO grants. Applications publish after 18 months.

Capital timeline

Latest events

Jul 2026Federal grantHealth and Human S · Phase I · Next generation multi-antigen Staphylococcus aureus vaccine enabled by proprietary mutant bacteriophage Qbeta$300K
Jan 2026Private capital raisedForm D · SEC · 2nd filing$570K
Jan 2023Private capital raisedForm D · SEC · 1st filing$438K
Jun 2022Federal grantHealth and Human S · Phase I · Development of proprietary bacteriophage Qbeta as a vaccine carrier platform for anti-salmonella vaccine$295K
Mar 2022Federal grantNSF · Phase II · SBIR Phase II:A Novel Bacteriophage Mutant as a Platform Carrier for Next Generation Vaccines$1.4M
Jul 2021Federal grantHealth and Human S · Phase I · Development of proprietary bacteriophage Qbeta as a vaccine carrier platform for anti-salmonella vaccine$595K
Jul 2021Federal grantHealth and Human S · Phase I · Development of proprietary bacteriophage Qbeta as a vaccine carrier platform for anti-salmonella vaccine$300K

Show 3 earlier federal awards

Sep 2020Federal grantHealth and Human S · Phase I · A Novel Vaccine Strategy to Target Breast Cancer Enabled by Proprietary Mutant Bacteriophage Qbeta-Tumor Antigen Conjugates$300K
Sep 2020Federal grantHealth and Human S · Phase I · A Novel Vaccine Strategy to Target Breast Cancer Enabled by Proprietary Mutant Bacteriophage Qbeta-Tumor Antigen Conjugates$300K
Jun 2019Federal grantNSF · Phase I · SBIR Phase I: Development of Bacteriophage Qbeta and Mutants as Carriers for Next Generation Vaccines$225K

Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.

Federal first

43months

from IASO THERAPEUTICS, INC.’s first federal award to its first private round.

First federal award · Jun 2019: NSF · $225K
First Form D · Jan 2023: $438K · 1st Form D
Awards before first raise: 7 awards

An association in public records, not a cause or a prediction.

Standing among 514 peers

Line = median

Biotech · Molecule

Federal grantsBelow median

Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.

Founders and team

Researcher links verified by same-company patents and grants

Herbert KavunjaResearcherExecutive OfficerLinked by $2.5M in grants as PI
Donald ParfetDirectorNamed in SEC Form D filings
Jeffrey WesleyDirectorNamed in SEC Form D filings
Robert ForgeyExecutive Officer, DirectorNamed in SEC Form D filings
Steve KuemmerieDirectorNamed in SEC Form D filings
Xuefei HuangExecutive Officer, DirectorNamed in SEC Form D filings

What it has protected

No granted patents are on record.

USPTO usually publishes applications 18 months after filing, so recent applications may not be visible yet. Patents assigned under a different entity name won’t match.

Checked: USPTO granted patents and published applications · Oct 23, 2026

IASO THERAPEUTICS INCShares a founder: Herbert W Kavunja
Ibex Investment Holdings LLCSimilar federal contract value in Biotech · null in contracts
CASCADE BIOCATALYSTS INC.Similar federal contract value in Biotech · null in contracts
ISLEX THERAPEUTICS, LLCSimilar federal contract value in Biotech · null in contracts
LifEngine Animal Health Laboratories IncorporatedSimilar federal contract value in Biotech · null in contracts
VERISIM LIFE, INC.Similar federal contract value in Biotech · null in contracts

Regulatory activity · Biotech

Sector-level, not company-level

07 Jul 2026New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
30 Jun 2026Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
30 Jun 2026Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
29 Jun 2026Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
26 Jun 2026Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
26 Jun 2026Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.

Sources

Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.

How to read this page

Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.

Data freshness

SEC Form D filings through Oct 23, 2026. SBIR and STTR awards through Oct 21, 2026.